Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.

Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T

Calcified tissue international21 Aug 2013Cited by 21 (Europe PMC)

PMID23963633PMCIDPMC3899450DOI10.1007/s00223-013-9777-8PepBankPUB-23963633

Summary

We conducted a randomized, double-blind trial to assess the effect of 28.2 μg teriparatide versus placebo (1.4 μg teriparatide) on reduction of the incidence of vertebral fractures. Individuals enrolled in this study included patients with primary osteoporosis with one to five vertebral fractures and capable of self-supported walking. Attention was focused on incident vertebral fractures, change in bone mineral density (BMD) of the lumbar spine, and safety. A total of 316 subjects participated in the study, which lasted up to 131 weeks. Incident vertebral fractures occurred in 3.3% of subjects in the 28.2 μg teriparatide-treated group and 12.6% of subjects in the placebo group during the 78-weeks study period. Kaplan-Meier estimates of risk after 78 weeks were 7.5 and 22.2 % in the teriparatide and placebo groups, respectively, with a relative risk reduction of 66.4% by teriparatide (P = 0.008). Lumbar BMD in the 28.2 μg teriparatide group increased significantly by 4.4 ± 4.7 % at 78 weeks, which was significantly higher than the corresponding data in the placebo group (P = 0.001). Adverse events were observed in 86.7% of individuals in the teriparatide group and 86.1% of those in the placebo group. In conclusion, weekly injection of a low-dose of teriparatide (28.2 μg) reduced the risk of incident vertebral fractures and increased lumbar BMD.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with primary osteoporosis, weekly teriparatide reduced incident vertebral fractures compared with placebo during 78 weeks.
In plain wordsIn patients with osteoporosis, weekly teriparatide reduced new vertebral fractures compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseIncident vertebral fractures
Study
n = 316
Comparator
placebo (1.4 μg teriparatide)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
28.2 μg once weekly · injection · 78 weeksAs given in this study (human).
Measurements
Incident vertebral fractures
3.3%
teriparatide
Incident vertebral fractures
12.6%
placebo
Source sentences
Summary
Incident vertebral fractures occurred in 3.3% of subjects in the 28.2 μg teriparatide-treated group and 12.6% of subjects in the placebo group during the 78-weeks study period.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blind trial to assess the effect of 28.2 μg teriparatide versus placebo (1.4 μg teriparatide) on reduction of the incidence of vertebral fractures. Individuals enrolled in this study included patients with primary osteoporosis with one to five vertebral fractures and capable of self-supported walking.
Title · context
Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg)
Show in the study text Report a problemFND-2396363301
02HumanRandomized controlled trialEfficacy outcome
In patients with primary osteoporosis, teriparatide reduced estimated vertebral fracture risk compared with placebo at 78 weeks.
In plain wordsIn patients with osteoporosis, teriparatide reduced estimated vertebral fracture risk compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseKaplan-Meier vertebral fracture risk
Study
n = 316
Comparator
placebo (1.4 μg teriparatide)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
28.2 μg once weekly · injection · 78 weeksAs given in this study (human).
Measurements
Estimated fracture risk
7.5%
teriparatide
Estimated fracture risk
22.2%
placebo
Relative risk reduction
66.4%
teriparatide versus placebo
Source sentences
Summary
Kaplan-Meier estimates of risk after 78 weeks were 7.5 and 22.2 % in the teriparatide and placebo groups, respectively, with a relative risk reduction of 66.4% by teriparatide (P = 0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blind trial to assess the effect of 28.2 μg teriparatide versus placebo (1.4 μg teriparatide) on reduction of the incidence of vertebral fractures. Individuals enrolled in this study included patients with primary osteoporosis with one to five vertebral fractures and capable of self-supported walking.
Title · context
Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg)
Show in the study text Report a problemFND-2396363302
03HumanRandomized controlled trialEfficacy outcome
In patients with primary osteoporosis, teriparatide increased lumbar BMD more than placebo at 78 weeks.
In plain wordsIn patients with osteoporosis, teriparatide increased lower-spine bone density more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar BMD
Study
n = 316
Comparator
placebo (1.4 μg teriparatide)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
28.2 μg once weekly · injection · 78 weeksAs given in this study (human).
Measurements
Lumbar BMD increase
4.4%
teriparatide at 78 weeks
Source sentences
Summary
Lumbar BMD in the 28.2 μg teriparatide group increased significantly by 4.4 ± 4.7 % at 78 weeks, which was significantly higher than the corresponding data in the placebo group (P = 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blind trial to assess the effect of 28.2 μg teriparatide versus placebo (1.4 μg teriparatide) on reduction of the incidence of vertebral fractures. Individuals enrolled in this study included patients with primary osteoporosis with one to five vertebral fractures and capable of self-supported walking.
Title · context
Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg)
Show in the study text Report a problemFND-2396363303
04HumanRandomized controlled trialSafety outcome
Adverse events occurred in 86.7% of teriparatide recipients and 86.1% of placebo recipients with primary osteoporosis.
In plain wordsAdverse events occurred in 86.7% of teriparatide recipients and 86.1% of placebo recipients.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableAdverse events
Study
n = 316
Comparator
placebo (1.4 μg teriparatide)
Outcome group
Adverse events · Whole body
Studied dose
28.2 μg once weekly · injectionAs given in this study (human).
Measurements
Adverse events
86.7%
teriparatide
Adverse events
86.1%
placebo
Source sentences
Summary
Adverse events were observed in 86.7% of individuals in the teriparatide group and 86.1% of those in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blind trial to assess the effect of 28.2 μg teriparatide versus placebo (1.4 μg teriparatide) on reduction of the incidence of vertebral fractures. Individuals enrolled in this study included patients with primary osteoporosis with one to five vertebral fractures and capable of self-supported walking.
Title · context
Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg)
Show in the study text Report a problemFND-2396363304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.